# AMPLIFY-7P (NCT05726864)

> A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05726864
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Elicio Therapeutics
- Conditions: Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; KRAS G12D; KRAS G12R; KRAS G12V; KRAS G12A; KRAS G12C; KRAS G12S; KRAS G13D; NRAS G12D; NRAS G12R; NRAS G12V; NRAS G12C; NRAS G12S
- Interventions: ELI-002 7P
- Enrollment: 158
- Primary outcome: Phase 1: Evaluate the safety of ELI-002 7P
- Primary outcome: Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8
- YouTube: 2
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=amplify-7p-nct05726864

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05726864", "email": "<work email>"}; the inbox owner confirms by the emailed link.